WO1995000662A1 - Diagnostic reagent stabilizer - Google Patents

Diagnostic reagent stabilizer Download PDF

Info

Publication number
WO1995000662A1
WO1995000662A1 PCT/US1994/007223 US9407223W WO9500662A1 WO 1995000662 A1 WO1995000662 A1 WO 1995000662A1 US 9407223 W US9407223 W US 9407223W WO 9500662 A1 WO9500662 A1 WO 9500662A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
succinic acid
salt
millimolar
sufficient amount
Prior art date
Application number
PCT/US1994/007223
Other languages
French (fr)
Inventor
Joseph E. Bateson
Original Assignee
Boehringer Mannheim Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Corporation filed Critical Boehringer Mannheim Corporation
Priority to DE0705348T priority Critical patent/DE705348T1/en
Priority to NZ268301A priority patent/NZ268301A/en
Priority to DE9422352U priority patent/DE9422352U1/en
Priority to DE69427911T priority patent/DE69427911T2/en
Priority to CA002165663A priority patent/CA2165663C/en
Priority to JP50312095A priority patent/JP3839470B2/en
Priority to EP94920320A priority patent/EP0705348B1/en
Priority to AU71160/94A priority patent/AU680520B2/en
Publication of WO1995000662A1 publication Critical patent/WO1995000662A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/005Enzyme electrodes involving specific analytes or enzymes
    • C12Q1/006Enzyme electrodes involving specific analytes or enzymes for glucose
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104998Glucose, ketone, nitrate standard or control
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • Y10T436/144444Glucose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2525Stabilizing or preserving

Definitions

  • This invention relates to the stabilization of compositions that include glucose oxidase and/or ferricyanide.
  • compositions such as diagnostic reagent compositions, that include glucose oxidase or ferricyanide have poor stability due to the tendency for glucose oxidase and ferricyanide to degrade.
  • Succinic acid and some salts of succinic acid have been used in the following references as a stabilizing agent (stabilizing, for example, a detergent composition) or a chelating agent: Boskamp.
  • a stabilizing agent stabilizing, for example, a detergent composition
  • a chelating agent Boskamp.
  • the invention is a stable composition of matter useful as a diagnostic reagent for the analysis of glucose from a fluid sample and a process for stabilizing compositions that include glucose oxidase and/or ferricyanide.
  • the invention is based upon the surprising result that the inclusion of succinic acid or a salt thereof will stabilize a composition that includes glucose oxidase and/or ferricyanide.
  • the succinic acid or a salt thereof is disodium succinate, which is utilized in a diagnostic reagent useful for the analysis of glucose in a biosensor.
  • the reagent is preferably made up in an aqueous slurry that includes glucose oxidase, potassium phosphate (buffer), potassium ferricyanide (a redox mediator), a dispersant and crystallization inhibitor, such as AVICEL RC - 591 F, which is a blend of 88% microcrystalline cellulose and 12% sodium carboxymethylcellulose, a small amount of hydroxyethylcellulose, a surfactant (such as TRITON X-100 surfactant, which includes various polyoxyethylene ethers), and water.
  • the resulting slurry may be coated onto the surface of working and counter electrodes in an electrochemical biosensor, dried, and subsequently utilized in the measurement of glucose from a fluid sample, as described herein.
  • succinic acid or a salt thereof may stabilize other compositions of matter that include either glucose oxidase and/or ferricyanide, such as various kinds of glucose test reagents that utilize either glucose oxidase and/or ferricyanide.
  • Fig. 1 is a schematic top view of a biosensor which may utilize the stable composition of the present invention.
  • Fig. 2 is a schematic elevation of the biosensor of Fig. 1 along lines 2-
  • Fig. 3 is a schematic top view of the biosensor of Fig. 2. Description of the Invention A specific embodiment of the present invention will first be described.
  • This specific embodiment utilizes a reagent that has been made more stable by the inclusion of disodium succinate.
  • a protocol for making the reagent is as follows:
  • Step 1 Prepare 1 liter (in a volumetric flask) of a buffer/NATROSOL mixture by adding 1.2 grams (g) hydroxyethylcellulose (sold under the mark NATROSOL
  • Step 2 Prepare an AVICEL mixture by stirring 14 g AVICEL
  • Step 3 Prepare a TRITON mixture by adding 0.5 g TRITON X-
  • Step 4 While stirring, add the total TRITON mixture dropwise with a dropwise addition funnel or buret to the total AVICEL mixture. Once addition is complete, continue stirring overnight.
  • Step 5 To the mixture resulting from Step 4, add, while stirring, 98.8 g potassium ferricyanide. (Add a little potassium ferricyanide at a time to allow the potassium ferricyanide to dissolve as added.)
  • Step 6 Stir the resulting mixture of Step 5 for 20 minutes.
  • Step 7 Adjust the pH of the mixture resulting from Step 6 to 6.25 by adding potassium hydroxide.
  • Step 8 To the resulting mixture of Step 7, add 9.2 g glucose oxidase (218.5 ortho-dianisidine units per milligram (mg) from Biozyme) and stir at least 20 minutes.
  • Step 9 To the resulting mixture of Step 8, add 10 g (37 millimoles (mmol)) disodium succinate hexahydrate and stir at least 20 minutes.
  • Step 10 - Filter the resulting mixture of Step 9 through a 100 micron sieve bag to remove any AVICEL clumping.
  • the filtrate is the resulting reagent composition 11 (see Fig.2), which is added to the electrode surfaces of the electrochemical biosensor, described below, and is then dried. (Before drying, this composition is 0.37 molar in phosphate buffer. A more preferred formulation is made 0.25 molar in phosphate buffer.
  • the final activity of glucose oxidase in the composition is preferably 1.57 tetramethylbenzidine
  • biosensor 1 comprises first and second electrically insulating layers 2 and 3, respectively. Any useful insulating material will be suitable. Typically, plastics, such as vinyl polymers and polyimides provide the electrical and structural properties which are desired.
  • the biosensor shown in FIGS. 1 through 3 is intended to be mass produced from rolls of material, necessitating the selection of a material which is sufficiently flexible for roll processing and at the same time sufficiently stiff to give a useful stiffness to the finished biosensor.
  • Layers 2 and 3 may be of any useful thickness. In a preferred embodiment, layer 2 is about 360 microns thick and layer 3 is about 250 microns thick.
  • Working electrode 4 and counter electrode 5 are preferably deposited on a backing of insulator material 7, such as polyimide, to reduce the possibility of tearing the electrode before it is affixed to layer 2.
  • Working electrode 4 and counter electrode 5 are substantially the same size and are made of the same electrically conducting material. Examples of electrically conducting materials that may be used are palladium, platinum, gold, silver, carbon, titanium, and copper. Noble metals are preferred because they provide a more constant, reproducible electrode surface area. Palladium is particularly preferred because it is one of the more difficult noble metals to oxidize and because it is a relatively inexpensive noble metal. Silver is not preferred because it is more readily oxidized by air than the other noble metals listed above.
  • electrodes 4 and 5 are about 0.1 micron thick and backing 7 is about 25 microns thick (commercially available from Courtalls-Andus Performance Films in California and Southwall Technologies, Inc.) (Fig 2).
  • Electrodes 4 and 5 must be sufficiently separated so that the electrochemical events at one electrode do not interfere with the electrochemical events at the other electrode.
  • the preferred distance between electrodes 4 and 5 is about 1.2 millimeters (mm).
  • electrodes 4 and 5, affixed to backing 7, are unspooled from reels and attached to layer 2 by the use of hot melt adhesive (not shown).
  • Electrodes 4 and 5 also preferably extend from one end of layer 2 to the other end in parallel configuration. (Fig. 1)
  • Insulating layer 3 is fixed on top of layer 2 and electrodes 4 and 5 by the use of hot melt adhesive (not shown).
  • Layer 3 includes cutout portion 8, which defines reagent well 9 and exposes substantially equal surface areas 10 of electrodes 4 and 5.
  • cutout 8 is 4 mm by 6 mm and electrodes 4 and 5 are each 1.5 mm in width. Therefore a surface area of about 6 mm 2 is exposed for each of the two electrodes.
  • Biosensor 1 also includes a power source (not shown) in electrical connection with the working and counter electrodes and a current measuring meter (not shown) which is also in electrical connection with the working and counter electrodes.
  • Biosensor reagent 11 (Fig. 2) is placed in well 9 so that it covers substantially all of exposed surfaces 10 of electrodes 4 and 5 and preferably covers the exposed surface of layer 2 between the electrodes.
  • reagent 11 made by the above-stated protocol is added to well 9 formed by cutout 8. This amount of reagent 11 will substantially cover surface areas 10 on both electrodes (Figs. 1 and 2) and will also contain a sufficient amount of reagent to perform an assay for glucose (described below).
  • Reagent 11 is then dried by heating at about 50° C for about 3 minutes. Drying removes at least about 90% of the water content of the reagent, thereby resulting in a dried reagent.
  • a polyester or nylon mesh 13 (Figs. 2 and 3) is preferably placed on top of the dried reagent to aid in preventing loss of reagent from the biosensor during shipping and handling and to aid in minimizing human contamination from the reagent.
  • Mesh 13 is affixed to the biosensor by adhesive tape 14, which includes hole 15.
  • Hole 15 is the target area for adding a sample containing an analyte, such as glucose, to be measured by the biosensor. (Fig. 3)
  • the roll-formed biosensors are separated by die punching to form discrete biosensors, which are used in conjunction with a power source (i.e., a battery) in electrical connection with the working and counter electrodes and a meter for measuring electrical current.
  • a power source i.e., a battery
  • the meter referred to above will normally be adapted to apply an algorithm to the current measurement, whereby an analyte concentration is provided and visually displayed. Improvements in such a power source and meter are the subject of commonly assigned U.S. Patent Number 4,963,814 issued October 16, 1990, U.S. Patent No. 4,999,632, issued March 12, 1991 , U.S. Patent No. 4,999,582, issued March 12, 1991 , and U.S. Patent Application Serial No. 07/451 ,305 (filed December 15, 1989; Notice of Allowance issued April 19, 1993), the disclosures of which are hereby incorporated by reference.
  • additional cutout portion 12 (Figs. 1 through 3), exposing portions of the working and counter electrodes, is preferably provided in the biosensor device.
  • the biosensor setup described above including the reagent may be used in conjunction with the power source and meter to measure glucose from a fluid sample, such as a blood sample.
  • a fluid sample such as a blood sample.
  • a blood sample (20 microliters ( ⁇ l) is sufficient) is added to reagent well 9, the reagent 11 is rehydrated, thereby solubilizing potassium ferricyanide, glucose oxidase (GOD), potassium phosphate buffer, disodium succinate and surfactant. If glucose is present in the blood sample, the following chemical reaction occurs:
  • GOD glucose + ferricyanide > gluconic acid + ferrocyanide.
  • the preferred reagent formulation was optimized for both stability and performance, as reflected by good assay precision, in a glucose assay performed with the above described biosensor strip. Stability studies show that this reagent formulation will have a stability greater than 2 years.
  • a reagent made by the protocol specified above was also stabilized when the included amount of disodium succinate hexahydrate varied from about 1/2% weight/volume of reagent slurry (about 18 and 1/2 millimolar (mM in succinate) to about 1 and 1/2% weight/volume of reagent slurry (about 55 mM in succinate). Further decreasing the amount of disodium succinate in the reagent below about 18 and 1/2 mM will cause further decreases in reagent stability.
  • reagent stability decreases until there is little, if any, stability.
  • Increasing the amount of the disodium succinate above about 55 mM in the reagent will further increase reagent stability, but only up to some upper limit where further addition of disodium succinate will not increase stability of the reagent.
  • Disodium succinate stabilizes both ferricyanide and glucose oxidase, thereby greatly retarding the decomposition of these reagent components and the resulting degradation of the reagent.
  • disodium succinate compositions that include either ferricyanide or glucose oxidase should also be stabilized by the inclusion of other succinate salts and by the inclusion of succinic acid itself. Stabilization will be observed irrespective of the reagent matrix.
  • the reagent matrix may be an aqueous slurry, as specified in the above protocol before drying of the reagent on the biosensor strip, an aqueous solution, or a dried matrix, such as the above specified reagent after drying on the biosensor strip, or a reagent incorporated into a film, membrane, or porous matrix, such as nylon nonwoven mesh.
  • the present invention may be applied to a wide variety of analytical and diagnostic reagents and apparatus that include either glucose oxidase or ferricyanide or both glucose oxidase and ferricyanide.
  • Succinic acid or a salt thereof may be included in the reagents and apparatus described in the following references, the disclosures of which are hereby incorporated by reference, as a reagent stabilizer: Nankai et al.. U.S. Patent No. 4,431 ,507, issued February 14,1984;

Abstract

The inclusion of succinic acid or a salt thereof to stabilize compositions that include glucose oxidase and/or ferricyanide. Typically, the succinic acid or succinic acid salt is included in a diagnostic reagent utilized in test strips or test solutions useful for the analysis of glucose from a fluid sample.

Description

DIAGNOSTIC REAGENT STABILIZER
Field of the Invention
This invention relates to the stabilization of compositions that include glucose oxidase and/or ferricyanide. Background of the Invention
Compositions, such as diagnostic reagent compositions, that include glucose oxidase or ferricyanide have poor stability due to the tendency for glucose oxidase and ferricyanide to degrade.
Succinic acid and some salts of succinic acid have been used in the following references as a stabilizing agent (stabilizing, for example, a detergent composition) or a chelating agent: Boskamp. U.S. Patent No. 4,532,064, issued July 30, 1984; Thomas, International Patent Application Publication
No. WO 86/04610, published August 14, 1986; Ramachandran et al.. U.S. Patent No. 4,900,475, issued February 13, 1990; Dormal et aL U.S. Patent No. 4,529,525, issued July 16, 1985; Penney. European Patent Specification EP O 072 581 B1 , issued April 8, 1987; JP 63202381 , published August 22, 1988; and JP 57138389, published August 26, 1982. None of these references discloses the use of succinic acid or a salt thereof to stabilize an aqueous or dried reagent that includes glucose oxidase and/or ferricyanide. Summary of the Invention
The invention is a stable composition of matter useful as a diagnostic reagent for the analysis of glucose from a fluid sample and a process for stabilizing compositions that include glucose oxidase and/or ferricyanide.
The invention is based upon the surprising result that the inclusion of succinic acid or a salt thereof will stabilize a composition that includes glucose oxidase and/or ferricyanide. Preferably, the succinic acid or a salt thereof is disodium succinate, which is utilized in a diagnostic reagent useful for the analysis of glucose in a biosensor. The reagent is preferably made up in an aqueous slurry that includes glucose oxidase, potassium phosphate (buffer), potassium ferricyanide (a redox mediator), a dispersant and crystallization inhibitor, such as AVICEL RC - 591 F, which is a blend of 88% microcrystalline cellulose and 12% sodium carboxymethylcellulose, a small amount of hydroxyethylcellulose, a surfactant (such as TRITON X-100 surfactant, which includes various polyoxyethylene ethers), and water. After mixing, the resulting slurry may be coated onto the surface of working and counter electrodes in an electrochemical biosensor, dried, and subsequently utilized in the measurement of glucose from a fluid sample, as described herein.
More broadly, succinic acid or a salt thereof may stabilize other compositions of matter that include either glucose oxidase and/or ferricyanide, such as various kinds of glucose test reagents that utilize either glucose oxidase and/or ferricyanide. Brief Description of the Drawings
Fig. 1 is a schematic top view of a biosensor which may utilize the stable composition of the present invention. Fig. 2 is a schematic elevation of the biosensor of Fig. 1 along lines 2-
2, and including the stable composition of the present invention and a cover mesh.
Fig. 3 is a schematic top view of the biosensor of Fig. 2. Description of the Invention A specific embodiment of the present invention will first be described.
This specific embodiment utilizes a reagent that has been made more stable by the inclusion of disodium succinate. A protocol for making the reagent is as follows:
Step 1 - Prepare 1 liter (in a volumetric flask) of a buffer/NATROSOL mixture by adding 1.2 grams (g) hydroxyethylcellulose (sold under the mark NATROSOL
250 M NF, available from Aqualon Company) to 0.74 molar (M) aqueous potassium phosphate and 26.4 g dibasic potassium phosphate at pH 6.25. Allow the buffer/NATROSOL mixture to stir and swell for 3 hours. Step 2 - Prepare an AVICEL mixture by stirring 14 g AVICEL
RC-591 F dispersant and crystallization inhibitor (available from FMC Corporation) and 504.8 g water for 20 minutes. Step 3 - Prepare a TRITON mixture by adding 0.5 g TRITON X-
100 surfactant to 514.6 g of the buffer/NATROSOL mixture and stir for 15 minutes.
Step 4 - While stirring, add the total TRITON mixture dropwise with a dropwise addition funnel or buret to the total AVICEL mixture. Once addition is complete, continue stirring overnight.
Step 5 - To the mixture resulting from Step 4, add, while stirring, 98.8 g potassium ferricyanide. (Add a little potassium ferricyanide at a time to allow the potassium ferricyanide to dissolve as added.) Step 6 - Stir the resulting mixture of Step 5 for 20 minutes.
Step 7 - Adjust the pH of the mixture resulting from Step 6 to 6.25 by adding potassium hydroxide. Step 8 - To the resulting mixture of Step 7, add 9.2 g glucose oxidase (218.5 ortho-dianisidine units per milligram (mg) from Biozyme) and stir at least 20 minutes. Step 9 - To the resulting mixture of Step 8, add 10 g (37 millimoles (mmol)) disodium succinate hexahydrate and stir at least 20 minutes. Step 10 - Filter the resulting mixture of Step 9 through a 100 micron sieve bag to remove any AVICEL clumping. The filtrate is the resulting reagent composition 11 (see Fig.2), which is added to the electrode surfaces of the electrochemical biosensor, described below, and is then dried. (Before drying, this composition is 0.37 molar in phosphate buffer. A more preferred formulation is made 0.25 molar in phosphate buffer. The final activity of glucose oxidase in the composition is preferably 1.57 tetramethylbenzidine
(TMB) megaunits per liter of composition before drying.) Referring to FIGS. 1 through 3, biosensor 1 comprises first and second electrically insulating layers 2 and 3, respectively. Any useful insulating material will be suitable. Typically, plastics, such as vinyl polymers and polyimides provide the electrical and structural properties which are desired. The biosensor shown in FIGS. 1 through 3 is intended to be mass produced from rolls of material, necessitating the selection of a material which is sufficiently flexible for roll processing and at the same time sufficiently stiff to give a useful stiffness to the finished biosensor.
Layers 2 and 3 may be of any useful thickness. In a preferred embodiment, layer 2 is about 360 microns thick and layer 3 is about 250 microns thick.
Working electrode 4 and counter electrode 5 are preferably deposited on a backing of insulator material 7, such as polyimide, to reduce the possibility of tearing the electrode before it is affixed to layer 2. Working electrode 4 and counter electrode 5 are substantially the same size and are made of the same electrically conducting material. Examples of electrically conducting materials that may be used are palladium, platinum, gold, silver, carbon, titanium, and copper. Noble metals are preferred because they provide a more constant, reproducible electrode surface area. Palladium is particularly preferred because it is one of the more difficult noble metals to oxidize and because it is a relatively inexpensive noble metal. Silver is not preferred because it is more readily oxidized by air than the other noble metals listed above. Preferably, electrodes 4 and 5 are about 0.1 micron thick and backing 7 is about 25 microns thick (commercially available from Courtalls-Andus Performance Films in California and Southwall Technologies, Inc.) (Fig 2).
Electrodes 4 and 5 must be sufficiently separated so that the electrochemical events at one electrode do not interfere with the electrochemical events at the other electrode. The preferred distance between electrodes 4 and 5 is about 1.2 millimeters (mm). In the preferred embodiment, electrodes 4 and 5, affixed to backing 7, are unspooled from reels and attached to layer 2 by the use of hot melt adhesive (not shown). Electrodes 4 and 5 also preferably extend from one end of layer 2 to the other end in parallel configuration. (Fig. 1)
Insulating layer 3 is fixed on top of layer 2 and electrodes 4 and 5 by the use of hot melt adhesive (not shown). Layer 3 includes cutout portion 8, which defines reagent well 9 and exposes substantially equal surface areas 10 of electrodes 4 and 5. In the preferred embodiment, cutout 8 is 4 mm by 6 mm and electrodes 4 and 5 are each 1.5 mm in width. Therefore a surface area of about 6 mm2 is exposed for each of the two electrodes.
Biosensor 1 also includes a power source (not shown) in electrical connection with the working and counter electrodes and a current measuring meter (not shown) which is also in electrical connection with the working and counter electrodes.
Biosensor reagent 11 (Fig. 2) is placed in well 9 so that it covers substantially all of exposed surfaces 10 of electrodes 4 and 5 and preferably covers the exposed surface of layer 2 between the electrodes.
In the embodiment described above, which is useful for glucose determination from a fluid sample, 6 microliters (μl) of reagent 11 made by the above-stated protocol is added to well 9 formed by cutout 8. This amount of reagent 11 will substantially cover surface areas 10 on both electrodes (Figs. 1 and 2) and will also contain a sufficient amount of reagent to perform an assay for glucose (described below).
Reagent 11 is then dried by heating at about 50° C for about 3 minutes. Drying removes at least about 90% of the water content of the reagent, thereby resulting in a dried reagent. After drying, a polyester or nylon mesh 13 (Figs. 2 and 3) is preferably placed on top of the dried reagent to aid in preventing loss of reagent from the biosensor during shipping and handling and to aid in minimizing human contamination from the reagent. Mesh 13 is affixed to the biosensor by adhesive tape 14, which includes hole 15. (Figs 2. and 3) Hole 15 is the target area for adding a sample containing an analyte, such as glucose, to be measured by the biosensor. (Fig. 3)
After drying the reagent and affixing the mesh, the roll-formed biosensors are separated by die punching to form discrete biosensors, which are used in conjunction with a power source (i.e., a battery) in electrical connection with the working and counter electrodes and a meter for measuring electrical current.
The meter referred to above will normally be adapted to apply an algorithm to the current measurement, whereby an analyte concentration is provided and visually displayed. Improvements in such a power source and meter are the subject of commonly assigned U.S. Patent Number 4,963,814 issued October 16, 1990, U.S. Patent No. 4,999,632, issued March 12, 1991 , U.S. Patent No. 4,999,582, issued March 12, 1991 , and U.S. Patent Application Serial No. 07/451 ,305 (filed December 15, 1989; Notice of Allowance issued April 19, 1993), the disclosures of which are hereby incorporated by reference. For easy electrical connection of the power source and meter, additional cutout portion 12 (Figs. 1 through 3), exposing portions of the working and counter electrodes, is preferably provided in the biosensor device.
The biosensor setup described above including the reagent, may be used in conjunction with the power source and meter to measure glucose from a fluid sample, such as a blood sample. When a blood sample (20 microliters (μl) is sufficient) is added to reagent well 9, the reagent 11 is rehydrated, thereby solubilizing potassium ferricyanide, glucose oxidase (GOD), potassium phosphate buffer, disodium succinate and surfactant. If glucose is present in the blood sample, the following chemical reaction occurs:
GOD glucose + ferricyanide > gluconic acid + ferrocyanide.
An incubation period (20 seconds is sufficient) for this reaction is allowed in order to let this reaction proceed to an end point, thereby building up a significant amount of ferrocyanide. Next, a potential difference is applied (by the power source) between working and counter electrodes sufficient to cause diffusion limited electrooxidation of ferrocyanide (converting the ferrocyanide to ferricyanide) at the surface of the working electrode. (About 300 millivolts potential difference is preferred.) The resulting diffusion limited current may be correlated to the amount of glucose in the blood sample.
The preferred reagent formulation, recited above, was optimized for both stability and performance, as reflected by good assay precision, in a glucose assay performed with the above described biosensor strip. Stability studies show that this reagent formulation will have a stability greater than 2 years. A reagent made by the protocol specified above was also stabilized when the included amount of disodium succinate hexahydrate varied from about 1/2% weight/volume of reagent slurry (about 18 and 1/2 millimolar (mM in succinate) to about 1 and 1/2% weight/volume of reagent slurry (about 55 mM in succinate). Further decreasing the amount of disodium succinate in the reagent below about 18 and 1/2 mM will cause further decreases in reagent stability. These further decreases in reagent stability may be described as a "tailing off' effect, wherein reagent stability decreases until there is little, if any, stability. Increasing the amount of the disodium succinate above about 55 mM in the reagent will further increase reagent stability, but only up to some upper limit where further addition of disodium succinate will not increase stability of the reagent.
The above reagent is stabilized by the inclusion of disodium succinate. Disodium succinate stabilizes both ferricyanide and glucose oxidase, thereby greatly retarding the decomposition of these reagent components and the resulting degradation of the reagent. Although the invention has been illustrated with disodium succinate, compositions that include either ferricyanide or glucose oxidase should also be stabilized by the inclusion of other succinate salts and by the inclusion of succinic acid itself. Stabilization will be observed irrespective of the reagent matrix. The reagent matrix may be an aqueous slurry, as specified in the above protocol before drying of the reagent on the biosensor strip, an aqueous solution, or a dried matrix, such as the above specified reagent after drying on the biosensor strip, or a reagent incorporated into a film, membrane, or porous matrix, such as nylon nonwoven mesh.
The present invention may be applied to a wide variety of analytical and diagnostic reagents and apparatus that include either glucose oxidase or ferricyanide or both glucose oxidase and ferricyanide. Succinic acid or a salt thereof may be included in the reagents and apparatus described in the following references, the disclosures of which are hereby incorporated by reference, as a reagent stabilizer: Nankai et al.. U.S. Patent No. 4,431 ,507, issued February 14,1984;
Nankai et al.. U.S. Patent No. 5,120,420, issued June 9, 1992; Wogoman. U.S. Patent No. 5,030,310, issued July 9, 1991 ; Senda et al.. U.S. Patent No. 4,820,399, issued April 11 , 1989; Nankai et al.. U.S. Patent No. 4,897,173, issued January 30, 1990;
Higgins et al.. U.S. Patent No. 4,545,382, issued October 8, 1985;
Mindt et al.. U.S. Patent No. 3,838,033, issued September 24, 1974
Nakamura et al.t U.S. Patent No. 4,224,125, issued September 23, 1980;
Hoenes et al.. U.S. Patent No. 5,122,244, issued June 16, 1992; Higgins et al.. U.S. Patent No. 4,711 ,245, issued December 8, 1987;
Davis et al.. U.S. Patent No. 4,758,323, issued July 19, 1988; Nakamura et al.. U.S. Patent No. 4,392,933, issued July 12, 1983; McNeil et al.. U.S. Patent No. 4,830,959, issued May 16, 1989; Phillips et al.. U.S. Patent No. 5,049,487, issued September 17, 1991 ;
Takizawa et al.. U.S. Patent No. 4,894,137, issued January 16, 1990;
Kawaαuri et al.. U.S. Patent No. 5,171 ,689, issued December 15, 1992;
Freitag. U.S. Patent No. 4,929,545, issued May 29, 1990; and Phillips et a U.S. Patent No. 5,059,394, issued October 22, 1991. (In some of these references, glucose oxidase has been cross-linked by chemical treatment (for example, by treatment with glutaraldehyde) or glucose oxidase has been covalently bound to the surface of an electrode. In such cases, the inclusion of succinic acid or a salt thereof may not additionally stabilize the reagent.)
The present invention has been disclosed in the above teachings and drawings with sufficient clarity and conciseness to enable one skilled in the art to make and use the invention, to know the best mode for carrying out the invention, and to distinguish if from other inventions and from what is old. Many variations and obvious adaptations of the invention will readily come to mind, and these are intended to be contained within the scope of the invention as claimed below.

Claims

I claim:
1. A process for stabilizing a composition containing glucose oxidase, comprising: adding a sufficient amount of succinic acid or a salt thereof to the composition to stabilize the composition.
2. A process for stabilizing a composition containing ferricyanide, comprising: adding a sufficient amount of succinic acid or a salt thereof to the composition to stabilize the composition.
3. A process for stabilizing a composition containing glucose oxidase and ferricyanide, comprising: adding a sufficient amount of succinic acid or a salt thereof to the composition to stabilize the composition.
4. The process of claim 3, wherein the concentration of succinic acid or a salt thereof is from about 18 1/2 millimolar to about 55 millimolar.
5. The process of claim 3, wherein the concentration of succinic acid or a salt thereof is about 37 millimolar.
6. The process of claim 4, wherein the succinic acid or a salt thereof is disodium succinate.
7. The process of claim 4, wherein the composition includes water, a dispersant and crystallization inhibitor in sufficient amount to form a slurry, and a buffer in sufficient amount to provide and maintain a pH at which glucose oxidase will catalyze the oxidation of glucose.
8. The process of claim 7, wherein the composition further includes a surfactant in sufficient amount to aid in rehydrating the composition with an aqueous sample after the slurry has been dried to form a dry reagent useful for the analysis of glucose in the sample.
9. The process of claim 8, wherein the succinic acid or a salt thereof is about 37 millimolar.
10. A composition of matter, comprising: glucose oxidase in an aqueous medium, or in a dried matrix; and succinic acid or a salt thereof in sufficient amount to stabilize the composition of matter.
11. The composition of claim 10, further comprising: a buffer in sufficient amount to provide and maintain a pH at which glucose oxidase will catalyze the oxidation of glucose.
12. The composition of claim 11 , further comprising: a ferricyanide in sufficient amount to function as a redox mediator in the catalytic oxidation of glucose.
13. The composition of claim 12, wherein the glucose oxidase is in the dried matrix and the composition further comprises a surfactant in sufficient amount to aid in rehydrating the composition when an aqueous sample is added to the dried matrix.
14. The composition of claim 12, wherein the glucose oxidase is in the aqueous medium formed by combining water and a dispersant and crystallization inhibitor.
15. The composition of claim 14, further comprising:
A surfactant in sufficient amount to aid in rehydrating the composition with an aqueous sample after the composition has been dried to form a dry reagent useful for the analysis of glucose in the aqueous sample.
16. The composition of claim 11 , wherein the concentration of succinic acid or a salt thereof is from about 18 1/2 millimolar to about 55 millimolar.
17. The composition of claim 14, wherein the concentration of succinic acid or a salt thereof is from about 18 1/2 millimolar to about 55 millimolar.
18. The composition of claim 14, wherein the concentration of succinic acid or a salt thereof is about 37 millimolar.
19. The composition of claim 18, wherein the succinic acid or a salt thereof is disodium succinate.
20. The composition of claim 15, wherein the concentration of succinic acid or a salt thereof is from about 18 1/2 millimolar to about 55 millimolar and the succinic acid or a salt thereof is disodium succinate.
PCT/US1994/007223 1993-06-21 1994-06-21 Diagnostic reagent stabilizer WO1995000662A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE0705348T DE705348T1 (en) 1993-06-21 1994-06-21 STABILIZER FOR DIAGNOSTIC REAGENTS
NZ268301A NZ268301A (en) 1993-06-21 1994-06-21 The stabilisation of diagnostic compositions comprising glucose oxidase and/or ferricyanide using succinic acid or a salt thereof
DE9422352U DE9422352U1 (en) 1993-06-21 1994-06-21 Stabilizer for a diagnostic reagent
DE69427911T DE69427911T2 (en) 1993-06-21 1994-06-21 STABILIZER FOR DIAGNOSTIC REAGENTS
CA002165663A CA2165663C (en) 1993-06-21 1994-06-21 Diagnostic reagent stabilizer
JP50312095A JP3839470B2 (en) 1993-06-21 1994-06-21 Diagnostic reagent stabilizer
EP94920320A EP0705348B1 (en) 1993-06-21 1994-06-21 Diagnostic reagent stabilizer
AU71160/94A AU680520B2 (en) 1993-06-21 1994-06-21 Diagnostic reagent stabilizer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8026393A 1993-06-21 1993-06-21
US08/080,263 1993-06-21

Publications (1)

Publication Number Publication Date
WO1995000662A1 true WO1995000662A1 (en) 1995-01-05

Family

ID=22156257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007223 WO1995000662A1 (en) 1993-06-21 1994-06-21 Diagnostic reagent stabilizer

Country Status (9)

Country Link
US (1) US5627075A (en)
EP (1) EP0705348B1 (en)
JP (1) JP3839470B2 (en)
AU (1) AU680520B2 (en)
CA (1) CA2165663C (en)
DE (3) DE69427911T2 (en)
ES (1) ES2154249T3 (en)
NZ (1) NZ268301A (en)
WO (1) WO1995000662A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901018A2 (en) * 1997-07-29 1999-03-10 Matsushita Electric Industrial Co., Ltd. Method for quantitative measurement of a substrate
EP0969089A1 (en) * 1998-06-29 2000-01-05 F. Hoffmann-La Roche Ag Phytase formulation
US6358722B1 (en) 1994-04-25 2002-03-19 Roche Vitamins, Inc. Heat tolerant phytases
US6391605B1 (en) 1997-03-25 2002-05-21 Roche Vitamins Inc. Modified phytases
US6579975B1 (en) 1997-07-24 2003-06-17 Roche Vitamins, Inc. Consensus phytases
US6699704B1 (en) 1994-04-25 2004-03-02 Roche Vitamins Inc. Heat tolerant phytases
EP1444333A2 (en) * 2001-10-23 2004-08-11 Medtronic MiniMed, Inc. Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property
CN1320112C (en) * 1998-06-29 2007-06-06 Dsmip资产有限公司 Phytase formulation
US8690796B2 (en) 2002-04-19 2014-04-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8845549B2 (en) 2002-04-19 2014-09-30 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US8845550B2 (en) 2001-06-12 2014-09-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8905945B2 (en) 2002-04-19 2014-12-09 Dominique M. Freeman Method and apparatus for penetrating tissue
US8945910B2 (en) 2003-09-29 2015-02-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5166198A (en) * 1996-11-08 1998-05-29 Mercury Diagnostics Inc. Opaque reaction matrix for the analysis of whole blood
US20050103624A1 (en) 1999-10-04 2005-05-19 Bhullar Raghbir S. Biosensor and method of making
US6413213B1 (en) 2000-04-18 2002-07-02 Roche Diagnostics Corporation Subscription based monitoring system and method
US6821410B2 (en) * 2001-03-07 2004-11-23 Matsushita Electric Industrial Co., Ltd. Biosensor and method of substrate quantification
WO2003046538A1 (en) * 2001-11-26 2003-06-05 Ischemia Technologies, Inc. Electrochemical detection of ischemia
US6759190B2 (en) * 2002-06-15 2004-07-06 Acon Laboratories, Inc. Test strip for detection of analyte and methods of use
AU2003234944A1 (en) * 2002-08-27 2004-03-18 Bayer Healthcare, Llc Methods of Determining Glucose Concentration in Whole Blood Samples
US7572237B2 (en) 2002-11-06 2009-08-11 Abbott Diabetes Care Inc. Automatic biological analyte testing meter with integrated lancing device and methods of use
US7175897B2 (en) * 2002-12-17 2007-02-13 Avery Dennison Corporation Adhesive articles which contain at least one hydrophilic or hydrophobic layer, method for making and uses for same
US8679853B2 (en) 2003-06-20 2014-03-25 Roche Diagnostics Operations, Inc. Biosensor with laser-sealed capillary space and method of making
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
PT1639352T (en) 2003-06-20 2018-07-09 Hoffmann La Roche Method and reagent for producing narrow, homogenous reagent strips
US7807043B2 (en) * 2004-02-23 2010-10-05 Oakville Hong Kong Company Limited Microfluidic test device
TW200718785A (en) 2005-11-10 2007-05-16 Toyo Boseki A process for improving the thermal stability of a composition containing a soluble coenzyme conjugated glucose dehydrogenase (GDH)
JP5583594B2 (en) * 2007-12-10 2014-09-03 バイエル・ヘルスケア・エルエルシー Method of depositing reagent substance in test sensor
EP2972260B1 (en) 2013-03-15 2018-07-11 Roche Diabetes Care GmbH Methods of scaling data used to construct biosensor algorithms
PL2972268T3 (en) 2013-03-15 2017-10-31 Hoffmann La Roche Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same
WO2014140177A2 (en) 2013-03-15 2014-09-18 Roche Diagnostics Gmbh Methods of detecting high antioxidant levels during electrochemical measurements and failsafing an analyte concentration therefrom as well as devices, apparatuses and systems incorporting the same
JP6352954B2 (en) 2013-03-15 2018-07-04 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Method and device for using information from recovery pulses in electrochemical analyte measurement, apparatus and system incorporating them
KR102007585B1 (en) 2014-11-03 2019-08-05 에프. 호프만-라 로슈 아게 Electrode arrangements for electrochemical test elements and methods of use thereof
JP2019529935A (en) 2016-10-05 2019-10-17 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト Detection reagents and electrode arrangements for multi-sample diagnostic test elements and methods of using them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886045A (en) * 1972-05-12 1975-05-27 Franco Meiattini Process for the enzymatic determination of glucose with a glucose-oxidase/peroxidase enzyme system
JPS57138389A (en) * 1981-02-17 1982-08-26 Toyobo Co Ltd Stable urease composition
EP0072581B1 (en) * 1978-09-20 1987-04-08 American Monitor Corporation The stabilization of working reagent solutions containing enzymes, and the use of such stabilized reagents in enzyme or substrate assays
US5185247A (en) * 1989-03-10 1993-02-09 Miles Inc. Stabilization of oxidase enzyme-based test strips

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1598322C2 (en) * 1967-06-30 1973-09-13 Calbiochem, Los Angeles, Calif. (Vst.A.) Laboratory reagent for the determination of glucose
US4189536A (en) * 1977-11-09 1980-02-19 Hycel, Inc. Reagent systems, enzymatic assays and compositions therefor
US4229369A (en) * 1979-04-25 1980-10-21 Hycel, Inc. Tris (hydroxymethyl) aminomethane salt of 2-mercaptosuccinic acid
JPS6033479B2 (en) * 1980-07-30 1985-08-02 協和醗酵工業株式会社 Method for quantifying hydrogen peroxide
JPS5886083A (en) * 1981-11-12 1983-05-23 Wako Pure Chem Ind Ltd Stabilizing agent for glycerol-3-phosphoric acid oxidase
JPS58128898A (en) * 1982-01-26 1983-08-01 Fuji Photo Film Co Ltd Treating liquid for making offset master hydrophilic
US4529525A (en) * 1982-08-30 1985-07-16 Colgate-Palmolive Co. Stabilized enzyme-containing detergent compositions
JPS59182361A (en) * 1983-03-31 1984-10-17 Kyowa Medetsukusu Kk Determination of hydrogen peroxide
GB8311314D0 (en) * 1983-04-26 1983-06-02 Unilever Plc Aqueous enzyme-containing compositions
JPS60108753A (en) * 1983-11-18 1985-06-14 Fuji Photo Film Co Ltd Multilayer chemical analysis element
WO1986004610A1 (en) * 1985-02-11 1986-08-14 Travenol-Genentech Diagnostics Stabilized enzyme substrate solutions
US4900475A (en) * 1985-07-26 1990-02-13 Colgate-Palmolive Co. Stabilized built liquid detergent composition containing enzyme
JPS63202381A (en) * 1987-02-17 1988-08-22 Agency Of Ind Science & Technol Stabilization of enzyme
US5116729A (en) * 1989-03-10 1992-05-26 Miles Inc. Stabilization of oxidase enzyme-based test strips

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886045A (en) * 1972-05-12 1975-05-27 Franco Meiattini Process for the enzymatic determination of glucose with a glucose-oxidase/peroxidase enzyme system
EP0072581B1 (en) * 1978-09-20 1987-04-08 American Monitor Corporation The stabilization of working reagent solutions containing enzymes, and the use of such stabilized reagents in enzyme or substrate assays
JPS57138389A (en) * 1981-02-17 1982-08-26 Toyobo Co Ltd Stable urease composition
US5185247A (en) * 1989-03-10 1993-02-09 Miles Inc. Stabilization of oxidase enzyme-based test strips

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358722B1 (en) 1994-04-25 2002-03-19 Roche Vitamins, Inc. Heat tolerant phytases
US6699704B1 (en) 1994-04-25 2004-03-02 Roche Vitamins Inc. Heat tolerant phytases
US6734004B2 (en) 1997-03-25 2004-05-11 Roche Vitamins Inc. Modified phytases
US6391605B1 (en) 1997-03-25 2002-05-21 Roche Vitamins Inc. Modified phytases
USRE39649E1 (en) 1997-07-24 2007-05-22 Dsm Ip Assets B.V. Consensus phytases
US6579975B1 (en) 1997-07-24 2003-06-17 Roche Vitamins, Inc. Consensus phytases
US7052869B2 (en) 1997-07-24 2006-05-30 Dsm Nutritional Products, Inc. Consensus phytases
EP0901018A3 (en) * 1997-07-29 2000-09-13 Matsushita Electric Industrial Co., Ltd. Method for quantitative measurement of a substrate
US6225078B1 (en) 1997-07-29 2001-05-01 Matsushita Electric Industrial Co., Ltd. Method for quantitative measurement of a substrate
EP0901018A2 (en) * 1997-07-29 1999-03-10 Matsushita Electric Industrial Co., Ltd. Method for quantitative measurement of a substrate
EP0969089A1 (en) * 1998-06-29 2000-01-05 F. Hoffmann-La Roche Ag Phytase formulation
CN1320112C (en) * 1998-06-29 2007-06-06 Dsmip资产有限公司 Phytase formulation
US9937298B2 (en) 2001-06-12 2018-04-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9802007B2 (en) 2001-06-12 2017-10-31 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8845550B2 (en) 2001-06-12 2014-09-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
EP1444333A2 (en) * 2001-10-23 2004-08-11 Medtronic MiniMed, Inc. Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property
EP1444333A4 (en) * 2001-10-23 2004-12-22 Medtronic Minimed Inc Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8845549B2 (en) 2002-04-19 2014-09-30 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US9186468B2 (en) 2002-04-19 2015-11-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8905945B2 (en) 2002-04-19 2014-12-09 Dominique M. Freeman Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9339612B2 (en) 2002-04-19 2016-05-17 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8690796B2 (en) 2002-04-19 2014-04-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9907502B2 (en) 2002-04-19 2018-03-06 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9498160B2 (en) 2002-04-19 2016-11-22 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US8945910B2 (en) 2003-09-29 2015-02-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation

Also Published As

Publication number Publication date
EP0705348A1 (en) 1996-04-10
DE9422352U1 (en) 2000-11-09
AU680520B2 (en) 1997-07-31
CA2165663C (en) 2004-11-23
DE69427911D1 (en) 2001-09-13
EP0705348B1 (en) 2001-08-08
ES2154249T3 (en) 2001-12-16
JP3839470B2 (en) 2006-11-01
ES2154249T1 (en) 2001-04-01
NZ268301A (en) 1997-10-24
DE705348T1 (en) 2000-10-05
DE69427911T2 (en) 2002-04-04
EP0705348A4 (en) 1998-05-27
CA2165663A1 (en) 1995-01-05
US5627075A (en) 1997-05-06
JPH08511942A (en) 1996-12-17
AU7116094A (en) 1995-01-17

Similar Documents

Publication Publication Date Title
AU680520B2 (en) Diagnostic reagent stabilizer
EP0505494B1 (en) Redox mediator reagent and biosensor
US5508171A (en) Assay method with enzyme electrode system
CA2167822C (en) Potentiometric biosensor and the method for its use
AU712527B2 (en) Electrochemical biosensor test strip
US5217594A (en) Convenient determination of trace lead in whole blood and other fluids
USRE36991E (en) Biosensor and method for producing the same
EP0352925B1 (en) Enzyme electrodes and improvements in the manufacture thereof
US5225064A (en) Peroxidase colloidal gold oxidase biosensors for mediatorless glucose determination
US5334296A (en) Peroxidase colloidal gold oxidase biosensors for mediatorless glucose determination
JP2001201479A (en) Biosensor
EP0695344B1 (en) Peroxidase colloidal gold oxidase biosensors for mediatorless glucose determination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 268301

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994920320

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2165663

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994920320

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994920320

Country of ref document: EP